Mary Malloy, MD

Co-director, Adult Lipid Clinic
Director, Pediatric Lipid Clinic
Endocrinologist

Dr. Mary Malloy is a metabolism specialist who cares for adults and children with cholesterol and triglyceride disorders, which can lead to the narrowing of arteries and cause other conditions, such as heart attack, stroke or pancreatitis. She serves as co-director of UCSF's lipid clinic for adults and director of the pediatric lipid clinic, which she established in 1971.

Malloy earned her medical degree at UCSF. She completed her residency in pediatrics at the University of Washington and UCSF, followed by a fellowship in pediatrics at UCSF.

Malloy's research interests have included lipoprotein metabolism, management of lipoprotein disorders, and the genetics of heart disease and stroke. She is a senior investigator in the UCSF Cardiovascular Research Institute. She has published widely on her research and clinical experience in journals and books.

Malloy is a fellow of the American Heart Association and a diplomate of the American Board of Clinical Lipidology. Physicians in the U.S. and abroad consult her on the diagnosis and management of complex cases involving lipoprotein disorders in children.

Clinics

Lipid Clinic
400 Parnassus Ave., Suite 550
San Francisco, CA 94143-1222
Phone: (415) 353-2350
Fax: (415) 353-2337

More about Mary Malloy

Education

UCSF 1962

Residencies

University of Washington and UCSF, Pediatrics 1965

Fellowships

UCSF, Pediatrics 1966

Selected Research and Publications

  1. Duell PB, Salen G, Eichler FS, DeBarber AE, Connor SL, Casaday L, Jayadev S, Kisanuki Y, Lekprasert P, Malloy MJ, Ramdhani RA, Ziajka PE, Quinn JF, Su KG, Geller AS, Diffenderfer MR, Schaefer EJ. Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis. J Clin Lipidol. 2018 Jun 22.
  2. Wang C, Najm R, Xu Q, Jeong DE, Walker D, Balestra ME, Yoon SY, Yuan H, Li G, Miller ZA, Miller BL, Malloy MJ, Huang Y. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat Med. 2018 Apr 09.
  3. Kane J, Schaefer E, Malloy M. Xenosterolemia: emerging molecular and clinical insights. Curr Opin Lipidol. 2017 Dec; 28(6):518-519.
  4. Stock EO, Ferrara CT, O'Connor PM, Naya-Vigne JM, Frost PH, Malloy MJ, Kane JP, Pullinger CR. Levels of prebeta-1 high-density lipoprotein are elevated in 3 phenotypes of dyslipidemia. J Clin Lipidol. 2018 Jan - Feb; 12(1):99-109.
  5. Alhariri A, Hamilton K, Oza V, Cordoro K, Sobreira NL, Malloy M, Slavotinek A. Clinical report: A patient with a late diagnosis of cerebrotendinous xanthomatosis and a response to treatment. Am J Med Genet A. 2017 Aug; 173(8):2275-2279.
  6. Quinn AG, Schwemberger R, Stock EO, Movsesyan I, Axtell A, Chang S, Ishida BY, Malloy MJ, Kane JP, Pullinger CR. Moderate statin treatment reduces prebeta-1 high-density lipoprotein levels in dyslipidemic patients. J Clin Lipidol. 2017 Jul - Aug; 11(4):908-914.
  7. Kane JP, Malloy MJ. Lipoproteins and amyloid vascular disease. Curr Opin Lipidol. 2016 Dec; 27(6):640-641.
  8. Kane JP, Malloy MJ. In memoriam: Richard J. Havel (1925-2016). J Lipid Res. 2016 May 12.
  9. Kane JP, Malloy MJ. Emerging molecular strategies for management of dyslipidemias. Curr Opin Lipidol. 2015 Dec; 26(6):601-2.
  10. Pullinger CR, Stock EO, Movsesyan I, Malloy MJ, Frost PH, Tripuraneni R, Quinn AG, Ishida BY, Schaefer EJ, Asztalos BF, Kane JP. Identification and metabolic profiling of patients with lysosomal acid lipase deficiency. J Clin Lipidol. 2015 Sep-Oct; 9(5):716-26.e1.
  11. Kane JP, Malloy MJ, Pullinger CR. HDL cholesterol efflux capacity and cardiovascular events. N Engl J Med. 2015 05 07; 372(19):1871.
  12. Malloy M, Miller B, Kane J. Apolipoprotein E and neurocognitive function--in reply. JAMA Neurol. 2015 Apr; 72(4):479.
  13. Malloy MJ, Kane JP. Congenital absence of apolipoprotein E and neurological function-reply. JAMA Neurol. 2014 Dec; 71(12):1579.
  14. Mak AC, Pullinger CR, Tang LF, Wong JS, Deo RC, Schwarz JM, Gugliucci A, Movsesyan I, Ishida BY, Chu C, Poon A, Kim P, Stock EO, Schaefer EJ, Asztalos BF, Castellano JM, Wyss-Coray T, Duncan JL, Miller BL, Kane JP, Kwok PY, Malloy MJ. Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function. JAMA Neurol. 2014 Oct; 71(10):1228-36.
  15. Kane J, Malloy MJ. Emerging roles of qualitative properties of lipoproteins in atherosclerosis. Curr Opin Lipidol. 2014 Oct; 25(5):406-7.
  16. Sharma V, Witkowski A, Witkowska HE, Dykstra A, Simonsen JB, Nelbach L, Beckstead JA, Pullinger CR, Kane JP, Malloy MJ, Watson G, Forte TM, Ryan RO. Aberrant hetero-disulfide bond formation by the hypertriglyceridemia-associated p.Gly185Cys APOA5 variant (rs2075291). Arterioscler Thromb Vasc Biol. 2014 Oct; 34(10):2254-60.
  17. Rowland CM, Pullinger CR, Luke MM, Shiffman D, Green L, Movsesyan I, Devlin JJ, Malloy MJ, Kane JP, Undas A. Lipoprotein (a), LPA Ile4399Met, and fibrin clot properties. Thromb Res. 2014 May; 133(5):863-7.
  18. Roberts JD, Hsu JC, Aouizerat BE, Pullinger CR, Malloy MJ, Kane JP, Olgin JE, Marcus GM. Impact of a 4q25 genetic variant in atrial flutter and on the risk of atrial fibrillation after cavotricuspid isthmus ablation. J Cardiovasc Electrophysiol. 2014 Mar; 25(3):271-277.
  19. Pullinger CR, Goldfine ID, Tanyola├ž S, Movsesyan I, Faynboym M, Durlach V, Chiefari E, Foti DP, Frost PH, Malloy MJ, Brunetti A, Kane JP. Evidence that an HMGA1 gene variant associates with type 2 diabetes, body mass index, and high-density lipoprotein cholesterol in a Hispanic-American population. Metab Syndr Relat Disord. 2014 Feb; 12(1):25-30.
  20. Kane JP, Malloy MJ. Needed: a better understanding of the antiatherogenic properties of HDL. Curr Opin Lipidol. 2013 Oct; 24(5):453-4.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.